Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance

Dianthus Therapeutics, Inc. /DE/

2026-Q1 EPS reported -$0.85

Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.
Cash $1.2B at March 31, including $719M gross from March public offering; runway into 2030.
Claseprubart: Early GO in CAPTIVATE CIDP trial; Phase 3 gMG trial mid-2026 with top-line 2H'28.
DNTH212: Priority indications SjD, SLE, DM; Phase 1 healthy volunteer data expected 2H'26.
Orphan Drug Designation for claseprubart in MG; FDA agreed to remove ANA screening and DIL reclassification.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.